|
Study of Erbitux (Cetuximab) in Patients with Metastatic Colorectal Carcinoma Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Study of Erbitux (Cetuximab) in Patients with Metastatic Colorectal Carcinoma conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Study of Erbitux (Cetuximab) in Patients with Metastatic Colorectal Carcinoma Clinical research trials and Study of Erbitux (Cetuximab) in Patients with Metastatic Colorectal Carcinoma health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Study of Erbitux (Cetuximab) in Patients with Metastatic Colorectal Carcinoma. Study of Erbitux (Cetuximab) in Patients with Metastatic Colorectal Carcinoma Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Study of Erbitux (Cetuximab) in Patients with Metastatic Colorectal Carcinoma clinical trial. Test subjects typically receive the most expert healthcare available for their Study of Erbitux (Cetuximab) in Patients with Metastatic Colorectal Carcinoma condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of Erbitux (Cetuximab) in Patients with Metastatic Colorectal Carcinoma  Study of Erbitux (Cetuximab) in Patients with Metastatic Colorectal Carcinoma
Study of Erbitux (Cetuximab) in Patients with Metastatic Colorectal Carcinoma
For Condition: Metastases, Neoplasm,Colorectal Neoplasms
Status: No longer recruiting
Sponsor(s): ImClone Systems ,
Synopsis: This is a phase II, multicenter, target enrollment of 250 evaluable patients, open-label study of cetuximab in patients with refractory, metastatic colorectal carcinoma. Based on prior studies, we predict that 70 to 75% of patients will be EGFR-positive. Patients must have documented failure after receiving either at least two chemotherapy regimens for metastatic disease or adjuvant therapy plus one chemotherapy regimen for metastatic disease provided that the patient progressed within 6 months of completing adjuvant therapy. Prior chemotherapy must have included irinotecan, oxaliplatin, and a fluoropyrimidine. Patients will receive an initial dose of cetuximab, 400 mg/m2, intravenously (i.v.) over 120 minutes, followed by weekly treatment with cetuximab, 250 mg/m2 i.v. over 60 minutes. Patients who experience unacceptable toxicity or who have progressive disease will not receive further cetuximab therapy. Patients will be evaluated for a tumor response at a minimum of every 6 weeks while on cetuximab therapy. Patients with stable disease or a partial or complete response may continue to receive weekly cetuximab therapy, unless they are dose-delayed or discontinued because of toxicity. Patients who have a partial or complete response must have a confirmatory tumor assessment no less than 4 weeks after the initial evaluation demonstrating a response. In addition, there is a pharmacokinetic companion protocol which will determine the trough and peak levels of cetuximab in 25 patients enrolled in the study at four to eight centers. A pharmacologic serum sample for the determination of levels of cetuximab will be obtained prior to the initial, fourth and sixth cetuximab infusions and 1 hour following the completion of the initial, fourth and sixth cetuximab infusions in the first course; and prior to and 1 hour post the completion of the first cetuximab infusion of each subsequent course of therapy. A course of therapy is defined as six weekly infusions of cetuximab monotherapy. ImClone will perform the pharmacokinetic analyses.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Provided signed written informed consent. - Histologically- or pathologically- confirmed metastatic colorectal carcinoma; - Documented progressive disease after receiving either: a) at least two chemotherapy regimens for metastatic disease or b) adjuvant therapy plus one chemotherapy regimen for metastatic disease provided that the patient progressed within 6 months of completing adjuvant therapy. Progressive disease will be defined as progression while on treatment or within 3 months after receiving the last dose of therapy in a given regimen; - Prior chemotherapy must have included irinotecan, oxaliplatin, and a fluoropyrimidine; - Measurable disease as defined in Section 3.3.2; - Immunohistochemical evidence of EGFr expression. Patients will be considered eligible if their tumors demonstrate any EGFr staining, regardless of the intensity, the cellular localization of the staining, or the percentage of cell staining. Patients who do not have tumor tissue available for EGFr testing will undergo biopsy of accessible tumor; - Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1 at study entry; - Adequate recovery from recent surgery, chemotherapy, and radiation therapy. At least 4 weeks must have elapsed from major surgery, prior chemotherapy, prior treatment with an investigational agent, or prior radiation therapy; - Accessible for treatment and follow-up. Patients enrolled in this trial must be treated at the participating center; - Men and woman age 18 years or older Source documentation of the prior treatment (eg, hospital/clinic records, radiographic reports) must be available to ImClone for review. Exclusion Criteria: Sex and Reproductive Status Exceptions - WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the study. - Women who are pregnant or breastfeeding. - Women with a positive pregnancy test on enrollment or prior to cetuximab administration. - Sexually active fertile men not using effective birth control. Medical History and Concurrent Diseases - Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent; - A serious uncontrolled medical disorder that would impair the ability of the patient to receive protocol therapy; - A history of uncontrolled angina, arrhythmias, congestive heart failure, or left ventricular ejection fraction (LVEF) below the institutional range of normal on a baseline multiple gated acquisition (MUGA) scan or echocardiogram (ECHO); - Known brain metastases; - Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of the cervix. Patients with a previous malignancy but without evidence of disease for greater than or equal to 5 years will be allowed to enter the trial; Physical and Laboratory Test Findings - Inadequate hematologic function defined by an absolute neutrophil count (ANC) <1,500/mm3, a platelet count <100,000/mm3, and a hemoglobin level <9 g/dL. - Inadequate hepatic function, defined by a total bilirubin level greater than or equal to 1.5 times the upper limit of normal (ULN) and aspartate transaminase (AST) and alanine transaminase (ALT) levels greater than or equal to 5 times the ULN. - Inadequate renal function defined by a serum creatinine level >1.5 times the ULN. Prohibited Therapies and/or Medications - A history of cetuximab or other therapy that targeted the EGF receptor; - A history of prior anti-cancer murine monoclonal antibody therapy; - Prisoners or patients who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (eg, infectious disease) illness.
Total Enrollment: 250
Location and Contact Information:
Additional Information:
Study ID Numbers: CP02-0144;
Study Start Date: August 2002
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00044863
Other Colorectal Neoplasms Studies:
1. Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma
2. Study of ABI-007 and Taxol in Patients with Metastatic Breast Cancer
3. Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
4. High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors
5. A Phase 3 Trial of ALIMTA (LY231514, pemetrexed) plus GEMZAR Versus GEMZAR in Patients with Unresectable or Metastatic Cancer of the Pancreas.
Related Studies:
Other Colorectal Neoplasms Clinical Trials
Other Clinical Trials
Other Clinical Trials
Study of Erbitux (Cetuximab) in Patients with Metastatic Colorectal Carcinoma
|
|
|
|
|
|
|
|
